SaNOtize Research & Development
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
#1-8755 Ash St, Vancouver, British Colum...Website
www.sanotize.comRevenue
$7.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About SaNOtize Research & Development
SaNOtize is a global pharmaceutical company that has developed a groundbreaking technology to harness the antimicrobial properties of nitric oxide (NO). Their innovative products, including a nasal spray, aim to provide protection against viruses. The company targets healthcare providers and potential business partners interested in advanced medical solutions. SaNOtize is committed to educating investors and partners about their technology and clinical development programs.Explore more
SaNOtize Research & Development Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SaNOtize Research & Development your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when SaNOtize Research & Development launches new products
Check if SaNOtize Research & Development has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
SaNOtize Research & Development, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at SaNOtize Research & Development
Earning: See what the market has to say on SaNOtize Research & Development recently announced quarterly report
Funding: Get notified immidiatlly once SaNOtize Research & Development has new funding data
Click to see if SaNOtize Research & Development had a recent Job posting/layoffs
Check out if SaNOtize Research & Development is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at SaNOtize Research & Development
Find 2 more new buyers
Compare Similar Companies to SaNOtize Research & Development
Compare insights from companies similar to SaNOtize Research & Development, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SaNOtize Research & Development is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SaNOtize Research & Development is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SaNOtize Research & Development.
SaNOtize Research & Development financials insights
Gather financial insights about SaNOtize Research & Development, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$2.5M
2022
Series B
$24M
SaNOtize Research & Development Tech Stack
A closer look at the technologies used by SaNOtize Research & Development
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Lateral Move
Executive Move
Board of Directors
New Hire
Executive Move
New Hire
Executive Move
SaNOtize Research & Development News & Media
SaNOtize’s Board Appoints Steven Basta as New Chief Executive Officer
VANCOUVER, British Columbia--(BUSINESS WIRE)--SaNOtize Research and Development Corp. (“SaNOtize”), a Canadian anti-infective-focused therapeutics company, today announced that the company has appointed Steven Basta, an experienced biopharma and medical device commercial leader, as its new Chief Executive Officer (CEO). Co-Founder Gilly Regev, PhD, will transition from her role as CEO to Chief Strategy and Innovation Officer at SaNOtize and will remain a member of its Board of Directors. For moSaNOtize Announces Inaugural Scientific Advisory Board
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #advisoryboard--SaNOtize Announces Inaugural Scientific Advisory BoardSaNOtize Names John Sharp Chief Financial Officer
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #newhire--SaNOtize Names John Sharp Chief Financial OfficerSaNOtize Announces $24 Million in Series B Funding to Advance Its Nitric Oxide-Based Therapeutics, Including Nasal Spray for the Treatment and Prevention of COVID-19
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #antimicrobial--SaNOtize announces $24 million in Series B financing to advance nitric oxide-based therapies for upper respiratory infections and topical diseases.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SaNOtize Research & Development
Sign Up For FreeTo access detailed company insights
SaNOtize is a global pharmaceutical company that has developed a groundbreaking technology to harness the antimicrobial properties of nitric oxide (NO). Their innovative products, including a nasal spray, aim to provide protection against viruses. The company targets healthcare providers and potential business partners interested in advanced medica... Read More
